Jafron Biomedical Co

Jafron Biomedical Co Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of Jafron Biomedical Co (300529.SZ) as of Nov 13, 2026 is 152.88. In the previous year, Cash Conversion Cycle (CCC) was 160.65 — a change of -4.84% (lower).

Cash Conversion Cycle

152.88

YoY

-4.84%

Last updated:

Cash Conversion Cycle (CCC) of Jafron Biomedical Co is 2025 152.88 . Cash Conversion Cycle (CCC) of Jafron Biomedical Co was 2024 160.65 . It decreases by -4.84% lower compared to the previous year.

The Jafron Biomedical Co Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2018
119.53 CNY
Jan 1, 2019
150.32 CNY
Jan 1, 2020
120.61 CNY
Jan 1, 2021
159.96 CNY
Jan 1, 2022
215.34 CNY
Jan 1, 2023
247.07 CNY
Jan 1, 2024
160.65 CNY
Jan 1, 2025
152.88 CNY
The Jafron Biomedical Co Cash Conversion Cycle history
YEARCash Conversion CycleYoY
152.88-4.84%
160.65-34.98%
247.07+14.74%
215.34+34.62%
159.96+32.62%
120.61-19.76%
150.32+25.76%
119.53+2.41%
116.71-34.51%
178.20+105.96%
86.52-56.49%
198.88—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Jafron Biomedical Co Stock analysis

What does Jafron Biomedical Co do? Jafron Biomedical Co., Ltd. generates revenue through the research, development, production, and sale of hemoperfusion products and medical equipment. The company offers a range of items including disposable hemoperfusion devices, hemoperfusion machines, disposable bilirubin adsorbers, the DX-10 blood purification machine, suture needles, and resins bandage. These products are utilized for treating conditions such as uremia, poisoning, severe liver diseases, autoimmune diseases, and multisystem organ failure. The primary customers for these medical solutions are hospitals across China, where the company’s products are applied in more than 3000 hospitals within 31 provinces. As a China-based company, Jafron Biomedical Co., Ltd. focuses on the design, manufacture, and distribution of biological materials and medical equipment to support healthcare providers in these regions. The company operates from its headquarters in Zhuhai, Guangdong, and supports its operations with a workforce of 3,003 full-time employees. By engaging in the full lifecycle of its products from research to sale, the firm serves the medical sector with specialized equipment for blood purification and related therapeutic needs. Jafron Biomedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Jafron Biomedical Co stock

Cash Conversion Cycle (CCC) of Jafron Biomedical Co is 152.88 in 2025.

Cash Conversion Cycle (CCC) of Jafron Biomedical Co changed from 160.65 to 152.88, representing a -4.84% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) Jafron Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s Jafron Biomedical Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Jafron Biomedical Co

All Key Metrics — Jafron Biomedical Co